A phase I trial of intranasal Moli1901 for cystic fibrosis.
about
Cystic fibrosis transmembrane conductance regulator dysfunction and its treatmentSpiperone, identified through compound screening, activates calcium-dependent chloride secretion in the airwayAirway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future.State of progress in treating cystic fibrosis respiratory disease.TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells.Can intervention in inositol phosphate signalling pathways improve therapy for cystic fibrosis?Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.Cystic fibrosis and estrogens: a perfect stormPhysiological roles and diseases of Tmem16/Anoctamin proteins: are they all chloride channels?Nasal potential difference measurements to assess CFTR ion channel activity.Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.Progress in cystic fibrosis and the CF Therapeutics Development NetworkNew pulmonary therapies directed at targets other than CFTR.New and Emerging Treatments for Cystic Fibrosis.Ribosomally synthesized and post-translationally modified peptide natural product discovery in the genomic era.Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.Improving the attrition rate of Lanthipeptide discovery for commercial applications.Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans.Emerging drug treatments for cystic fibrosis
P2860
Q26851242-5080F1F0-FD01-46CA-A397-80F6E9F1B63EQ28299931-EE8C4792-7E2B-4569-AA23-6DC5E50902A7Q33771660-149A5AD2-FE6A-42F2-94F9-E0D3FC30603AQ34375926-81FDD97D-223A-4482-A43D-5CEAEC1B423AQ34503314-7745BB13-4939-4AA8-BCBB-424F9B5EC33FQ36318568-B11BF4D6-2A9E-4FCC-8815-BD3C609FD89CQ36891541-957D1B57-FBB3-43EE-AF70-76C0FB36A9A7Q36972780-3AFC571C-3F74-42F1-8AF7-E3CBED3D2C08Q37130687-437A1342-2A05-4BD9-B382-B14017A6F97AQ37140714-E9298EC3-2220-4B4F-9183-4637A422837AQ37158668-1F8C8622-2669-4A72-B219-186FDD671B82Q37209004-BB6350B4-E9EE-4B1C-B645-3B84F4588CF6Q38111645-20053F0D-5AA5-4259-B810-342C80D7A5BDQ38532426-245E6CDE-2CE2-4628-A156-440AFE9DF323Q38928841-D5503D93-7C5E-4020-AD32-6C351222DB70Q41840137-79F69513-0597-409A-8674-EA9812056CAEQ47383314-6E8CE98A-A157-4C6A-BEEE-9618172F0633Q51712533-5811331C-5860-417C-9F11-993C9BBABE91Q57952080-87C466BF-E534-4E9D-8540-867F22651ACE
P2860
A phase I trial of intranasal Moli1901 for cystic fibrosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A phase I trial of intranasal Moli1901 for cystic fibrosis.
@en
A phase I trial of intranasal Moli1901 for cystic fibrosis.
@nl
type
label
A phase I trial of intranasal Moli1901 for cystic fibrosis.
@en
A phase I trial of intranasal Moli1901 for cystic fibrosis.
@nl
prefLabel
A phase I trial of intranasal Moli1901 for cystic fibrosis.
@en
A phase I trial of intranasal Moli1901 for cystic fibrosis.
@nl
P356
P1433
P1476
A phase I trial of intranasal Moli1901 for cystic fibrosis.
@en
P2093
Luis Molina
William B Guggino
P304
P356
10.1378/CHEST.125.1.143
P407
P577
2004-01-01T00:00:00Z